Analogifremgangsmåde til fremstilling af L-asparaginat af cyklisk erythromycin A 11,12-carbonat

1443097 L-Aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate INSTYTUT PRZEMYSLU FARMACEUTYCZNEGO 22 July 1974 [28 July 1973] 32396/74 Heading C2C The novel antibiotic, the L-aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate is obtained, optionally as the monohydrate, by reacting s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZDZISLAW SZYPKA, HALINA DAHLIG
Format:	Patent
Sprache:	dan
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY DERIVATIVES THEREOF HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	ZDZISLAW SZYPKA HALINA DAHLIG
description	1443097 L-Aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate INSTYTUT PRZEMYSLU FARMACEUTYCZNEGO 22 July 1974 [28 July 1973] 32396/74 Heading C2C The novel antibiotic, the L-aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate is obtained, optionally as the monohydrate, by reacting substantially stoichiometric proportions of the cyclic carbonate of erythromycin A 6,9-hemiacetal and L-aspartic acid in an aqueous medium (e.g. H 2 O, H 2 O/acetone, H 2 O/ethanol). To isolate the product, the resulting solution may be lyophilized or evaporated with, if necessary, addition of a liquid which forms a binary or ternary azeotropic mixture therewith.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DK137278BB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DK137278BB</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DK137278BB3</originalsourceid><addsrcrecordid>eNrjZEhwzEvMyU_PTCtKzU1PzEsvzj28NCVVoSQzRwEkVAxk5GTmpSskpin46CYWFyQWJaZn5iWWgASSK7NzMouzFVKLKksyivJzK5Mz8xQcFQwNdQyNdJMTi5LygQp5GFjTEnOKU3mhNDeDvJtriLOHbmpBfnwq0MDk1LzUkngXb0NjcyNzCycnY8IqABTUPIs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Analogifremgangsmåde til fremstilling af L-asparaginat af cyklisk erythromycin A 11,12-carbonat</title><source>esp@cenet</source><creator>ZDZISLAW SZYPKA ; HALINA DAHLIG</creator><creatorcontrib>ZDZISLAW SZYPKA ; HALINA DAHLIG</creatorcontrib><description>1443097 L-Aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate INSTYTUT PRZEMYSLU FARMACEUTYCZNEGO 22 July 1974 [28 July 1973] 32396/74 Heading C2C The novel antibiotic, the L-aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate is obtained, optionally as the monohydrate, by reacting substantially stoichiometric proportions of the cyclic carbonate of erythromycin A 6,9-hemiacetal and L-aspartic acid in an aqueous medium (e.g. H 2 O, H 2 O/acetone, H 2 O/ethanol). To isolate the product, the resulting solution may be lyophilized or evaporated with, if necessary, addition of a liquid which forms a binary or ternary azeotropic mixture therewith.</description><edition>2</edition><language>dan</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; DERIVATIVES THEREOF ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SUGARS</subject><creationdate>1978</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19780213&DB=EPODOC&CC=DK&NR=137278B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19780213&DB=EPODOC&CC=DK&NR=137278B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZDZISLAW SZYPKA</creatorcontrib><creatorcontrib>HALINA DAHLIG</creatorcontrib><title>Analogifremgangsmåde til fremstilling af L-asparaginat af cyklisk erythromycin A 11,12-carbonat</title><description>1443097 L-Aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate INSTYTUT PRZEMYSLU FARMACEUTYCZNEGO 22 July 1974 [28 July 1973] 32396/74 Heading C2C The novel antibiotic, the L-aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate is obtained, optionally as the monohydrate, by reacting substantially stoichiometric proportions of the cyclic carbonate of erythromycin A 6,9-hemiacetal and L-aspartic acid in an aqueous medium (e.g. H 2 O, H 2 O/acetone, H 2 O/ethanol). To isolate the product, the resulting solution may be lyophilized or evaporated with, if necessary, addition of a liquid which forms a binary or ternary azeotropic mixture therewith.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>DERIVATIVES THEREOF</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SUGARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1978</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZEhwzEvMyU_PTCtKzU1PzEsvzj28NCVVoSQzRwEkVAxk5GTmpSskpin46CYWFyQWJaZn5iWWgASSK7NzMouzFVKLKksyivJzK5Mz8xQcFQwNdQyNdJMTi5LygQp5GFjTEnOKU3mhNDeDvJtriLOHbmpBfnwq0MDk1LzUkngXb0NjcyNzCycnY8IqABTUPIs</recordid><startdate>19780213</startdate><enddate>19780213</enddate><creator>ZDZISLAW SZYPKA</creator><creator>HALINA DAHLIG</creator><scope>EVB</scope></search><sort><creationdate>19780213</creationdate><title>Analogifremgangsmåde til fremstilling af L-asparaginat af cyklisk erythromycin A 11,12-carbonat</title><author>ZDZISLAW SZYPKA ; HALINA DAHLIG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DK137278BB3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>dan</language><creationdate>1978</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>DERIVATIVES THEREOF</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SUGARS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZDZISLAW SZYPKA</creatorcontrib><creatorcontrib>HALINA DAHLIG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZDZISLAW SZYPKA</au><au>HALINA DAHLIG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Analogifremgangsmåde til fremstilling af L-asparaginat af cyklisk erythromycin A 11,12-carbonat</title><date>1978-02-13</date><risdate>1978</risdate><abstract>1443097 L-Aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate INSTYTUT PRZEMYSLU FARMACEUTYCZNEGO 22 July 1974 [28 July 1973] 32396/74 Heading C2C The novel antibiotic, the L-aspartate of cyclic erythromycin A 6,9-hemiacetal carbonate is obtained, optionally as the monohydrate, by reacting substantially stoichiometric proportions of the cyclic carbonate of erythromycin A 6,9-hemiacetal and L-aspartic acid in an aqueous medium (e.g. H 2 O, H 2 O/acetone, H 2 O/ethanol). To isolate the product, the resulting solution may be lyophilized or evaporated with, if necessary, addition of a liquid which forms a binary or ternary azeotropic mixture therewith.</abstract><edition>2</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	dan
recordid	cdi_epo_espacenet_DK137278BB
source	esp@cenet
subjects	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY DERIVATIVES THEREOF HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS
title	Analogifremgangsmåde til fremstilling af L-asparaginat af cyklisk erythromycin A 11,12-carbonat
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A33%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZDZISLAW%20SZYPKA&rft.date=1978-02-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDK137278BB%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true